The University of Chicago Header Logo

Connection

Walter M. Stadler to Clinical Trials, Phase II as Topic

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Clinical Trials, Phase II as Topic.
Walter M. Stadler
Connection Strength
1.570
Clinical Trials, Phase II as Topic
  1. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16.
    View in: PubMed
    Score: 0.382
  2. Other paradigms: randomized discontinuation trial design. Cancer J. 2009 Sep-Oct; 15(5):431-4.
    View in: PubMed
    Score: 0.320
  3. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther. 2007 Apr; 6(4):1180-5.
    View in: PubMed
    Score: 0.271
  4. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
    View in: PubMed
    Score: 0.091
  5. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
    View in: PubMed
    Score: 0.070
  6. Development of growth inhibitory agents in urological and other malignancies. BJU Int. 2006 Sep; 98(3):497-502.
    View in: PubMed
    Score: 0.064
  7. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
    View in: PubMed
    Score: 0.061
  8. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A. 2004 Sep; 43 Suppl 3:S145-6.
    View in: PubMed
    Score: 0.057
  9. Developing drugs that do not cause tumor regression. Clin Adv Hematol Oncol. 2003 Nov; 1(11):654-5.
    View in: PubMed
    Score: 0.053
  10. Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9.
    View in: PubMed
    Score: 0.047
  11. Metastatic bladder cancer: advances in treatment. Eur J Cancer. 1997 Jan; 33 Suppl 1:S23-6.
    View in: PubMed
    Score: 0.033
  12. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34.
    View in: PubMed
    Score: 0.032
  13. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995 Feb; 22(1):67-73.
    View in: PubMed
    Score: 0.029
  14. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.025
  15. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
    View in: PubMed
    Score: 0.024
  16. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.